I am not an employee then or now but i do know the company
I am not an employee then or now but i do know the company and players. When we, those very familiar with Medoc/Veneto, heard they were selling themselves as a revenue generating valued asset we couldnt believe it. Anyone and everyone who knew this company would stay far far away. Their business model was dead and toxic. Then when we learned that they were selling to a public company we got worried for the investors and i know people tried to warn generex executives that what they were buying may not actually be the same as what they were being told. They dismissed the warning. Ask yourselves, why the name switch to Veneto, meant to disguise Medoc, which you can very well see in the SEC financial disclosure that was the money making MSO componant? Why change all staff and executives profiles to eliminate all mention of Medoc and now Veneto? This is not being transparent to investors. I know what to look for so everything i am telling you is publicly discoverable. 3 pharmacies were transferred to Nugenerex. Those 3 closed this week. The staff was told they were subject to lay off. The ENTIRE business model and operation including all executives, regardless of what name they chose to operate under (they had 100s of llcs) was and is subject to investigation. This is not a business to revive from the dead unless you like jail time. What they did and how they did it, from top to bottom and involving all the executives and all the related companies is and was subject to federal and state investigation, and for good reason. I don't know generex or joe. Maybe they knew the whole story and maybe they didnt. But by now the whole picture should be coming into focus and you, the investors need to know the truth with VERIFIED TRUE INDEPENDENT review of that business. Show you the $. The real $ not purported. I know this asset you purchased, Veneto, and hear all the bs you are being told about who and what they are. I am only out to protect you. It is bad enough that this hunk of poop was repackaged to make bad people more money but the fact that they are doing it on the backs of public investors and someone isnt telling you the truth is probably another set of criminal offenses. If it turned out to be a bad deal then they should say that and they should hold those responsible accountable. And if i am wrong, no harm-no foul. I am done talking. I feel like this is being seen as some sort of attack on your company but it isnt. It is a warning for whomever wants to heed it. I am just tired of the little guys being taken advantage of. This is what message boards are for btw. Sharing information about investments. Good luck.
1
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...
Continue Reading
Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....
Continue Reading
Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...
Continue Reading
Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...
Continue Reading
Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...
Continue Reading
ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...
Continue Reading
Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...
Continue Reading
Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...
Continue Reading
They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...
Continue Reading
A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...
Continue Reading
Top 5 Most Recently Viewed Articles
Embracing the Shift in Sustainable Living Beko, a renowned leader in home appliances, recently unveiled its Smart Living Index (SLI), shedding light on how economic pressures are propelling households toward sustainable living choices. This extensive survey captured the changing perspectives of consumers globally regarding sustainability and energy efficiency. Insights...
Continue Reading
Admiral Markets AS Reports Strong Performance in 2024 Admiral Markets AS 2024 Financial Highlights In a year characterized by low volatility in financial markets, Admiral Markets AS has demonstrated impressive resilience. The company has successfully boosted its trading revenues and achieved a positive EBITDA, thanks to its rigorous cost control measures. This...
Continue Reading
E2open Recognized as a Leader in Supply Chain Planning E2open Parent Holdings, Inc. (NYSE: ETWO), a leading connected supply chain SaaS platform, has received significant acknowledgment by the IDC MarketScape. The company has been named a Leader in various IDC MarketScape reports, including the Worldwide Supply Chain Planning Overall 2024 Vendor Assessment, as well as...
Continue Reading
Exciting Addition to Wistar Institute's Research Team The Wistar Institute, a leader in innovative biomedical research, has made a significant announcement regarding their team structure. The esteemed institution has welcomed Katherine Aird, Ph.D. as the new co-leader and professor within the Molecular and Cellular Oncogenesis Program at the Ellen and Ronald Caplan Cancer...
Continue Reading
Challenges Ahead for Tesla Tesla Inc. (NASDAQ: TSLA), led by CEO Elon Musk, is bracing for a challenging phase as the availability of federal EV credits diminishes and tariff-related pressures escalate. The Impact of EV Credit Expiration During a recent earnings call, Musk indicated that the company might face a few difficult quarters due to the expiration of a...
Continue Reading
